To: 

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
| **Patient Name:** | *Patient Name:* [redacted] |
| **DOB:** | [redacted] |
| **Patient MRN:** | [redacted] |
| **Phone:** | (559) 972-7393 |
| **Hospital Sample ID Number:** | [redacted] |
| **Ordering Provider Name:** | Teske, Milton |
| **Location:** | Kings County Public Health Laboratory |
| **Sample ID:** | [redacted] |

### Coronavirus Disease 2019 PCR-Upper Respiratory

**Collected:** 8/24/2020 1:57 PM  
**Received:** 8/24/2020 4:13 PM  
**Approval Date:** 8/25/2020 12:45 PM  

**TaqPath COVID-19 Combo Kit Result:** SARS-CoV-2 Not Detected


The tests performed at the TCPHL have been made available by the FDA under an Emergency Use Authorization (EUA). Their use within the United States is limited to qualified laboratories, including the Tulare County Public Health Lab, with training, facilities and equipment appropriate for specimen handling, testing and interpretation of the results of these real-time RT-PCR assays. The EUA for these tests are supported by the Secretary of Health and Human Services' declaration that circumstances exist to justify the use of in-vitro diagnostics under EUA for the detection and/or diagnosis of SARS-CoV-2. This EUA will remain in effect for the duration of the SARS-CoV-2 emergency, unless terminated or revoked by the FDA. Results should be considered in the context of clinical observations and epidemiological data.

A laboratory result of "Not Detected" does not conclusively rule out disease. Tests on additional samples may be pending at the Tulare County Public Health Laboratory (TCPHL). Please review results as soon as they become available.

**Reporting Laboratories:** Tulare Public Health Lab (CLIA ID: 05D0667647)  
Lab Director: Miriam Lachica, MA  
1062 South “K” Street, Tulare, CA 93274  
Ph: 559.685.5750

**Report Status:** END OF REPORT (Final)
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To:

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To:

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tablespots, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [REDACTED]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [REDACTED]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]
DOB: [Redacted]

The result of your COVID-19 Nasal RT-PCR test that was administered on 11/05/2020 is Negative.

Your Public Health Department has been notified of this result as required by law.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use cloth face coverings when you are:
  - Inside of, or in line to enter, any indoor public place
  - Using public transportation, a taxi, private car service, or ride-sharing vehicle
  - Outside and unable to physical distance 6 feet (2 meters) away from others
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.
- Open windows and use a fan (if possible) in shared spaces for good airflow.
- Be alert for symptoms. Watch for fever, cough, shortness of breath, or other symptoms of COVID-19. Take your temperature if symptoms develop. Follow CDC guidance if symptoms develop.

If you were recently exposed to someone with COVID-19, you should still stay at home and self-quarantine (separate yourself from others) for 14 days, starting from the most recent day that you were possibly exposed to COVID-19. You should continue to monitor for symptoms for up to 14 days after your last possible exposure. If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
El resultado de su RT-PCR prueba de COVID-19 Nasal, realizada en 11/05/2020 es Negative.

Según lo exigido por la ley, se notificó este resultado a su Departamento de Salud Pública.

Si se siente bien y no tiene fiebre ni tos, puede reanudar sus actividades normales siguiendo las recomendaciones de su Departamento de Salud local y estatal con respecto a las órdenes de Quedarse en Casa o Refugio Designado.

Independientemente de su resultado, aún es importante que tome las siguientes medidas de cuidado en su hogar:

- Lávese bien las manos frecuentemente con agua y jabón durante al menos 20 segundos. Si no dispone de agua y jabón, use un desinfectante para manos que contenga al menos el 60% de alcohol. Evite tocarse los ojos, la nariz y la boca con las manos sin lavar.
- Para toser o estornudar, cúbrase la boca y la nariz con un pañuelo de papel y deséchelo inmediatamente. Si no dispone de pañuelos de papel, tosa/estornude en el pliegue del codo, no en las manos. Lávese bien las manos con agua y jabón inmediatamente después.
- Evite compartir utensilios, toallas, ropa de cama, ropa u otros artículos. Lave bien los artículos con agua y jabón.
- Practique el distanciamiento físico. Esto incluye evitar los lugares públicos concurridos donde podría haber un contacto estrecho con otras personas. Mantenga una distancia de 6 pies (2 metros) de otras personas, cuando sea posible. Evite el contacto con personas que estén enfermas.
- Use una mascarilla o un barbijo de tela casero cuando se encuentre en las siguientes situaciones:
  - Dentro de, o en la cola para ingresar en, cualquier lugar público cerrado
  - Usando el transporte público, un taxi, un servicio de automóvil privado o vehículo de viajes compartidos
  - Al aire libre sin poder mantener una distancia física de 6 pies (2 metros) de otras personas
- Use detergente de uso doméstico y agua para limpiar las superficies de contacto frecuente como encimeras, interruptores de luz, barandas, teléfonos, teclados, inodoros, canillas y picaportes. Las superficies sucias se deben limpiar, luego desinfectar con un desinfectante de uso doméstico común.
- Abra las ventanas y use un ventilador (si es posible) en espacios compartidos para que haya una buena circulación de aire.
- Esté alerta a los síntomas. Esté atento a la aparición de fiebre, tos, dificultad para respirar (disnea) u otros síntomas de COVID-19. Si aparecen síntomas, tómese la temperatura. Si aparecen síntomas, siga las recomendaciones de los CDC.
Si recientemente estuvo expuesto a alguien con COVID-19, debería quedarse en casa y ponerse en cuarentena (aislarse de los demás) durante 14 días, contados desde el último día en que estuvo posiblemente expuesto a la COVID-19. Debería seguir controlando los síntomas hasta 14 días después de su última posible exposición. Si tiene más preguntas, comuníquese con su proveedor de atención primaria. Ha sido un enorme privilegio ayudarle con su atención de la salud.
To: [Redacted]
DOB: [Redacted]

The result of your COVID-19 Nasal RT-PCR test that was administered on 11/05/2020 is Negative.

Your Public Health Department has been notified of this result as required by law.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use cloth face coverings when you are:
  - Inside of, or in line to enter, any indoor public place
  - Using public transportation, a taxi, private car service, or ride-sharing vehicle
  - Outside and unable to physical distance 6 feet (2 meters) away from others
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.
- Open windows and use a fan (if possible) in shared spaces for good airflow.
- Be alert for symptoms. Watch for fever, cough, shortness of breath, or other symptoms of COVID-19. Take your temperature if symptoms develop. Follow CDC guidance if symptoms develop.

If you were recently exposed to someone with COVID-19, you should still stay at home and self-quarantine (separate yourself from others) for 14 days, starting from the most recent day that you were possibly exposed to COVID-19. You should continue to monitor for symptoms for up to 14 days after your last possible exposure. If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
Para: [Nombre]
Fecha de nacimiento: [Fecha]

El resultado de su RT-PCR prueba de COVID-19 Nasal, realizada en 11/05/2020 es Negative.

Según lo exigido por la ley, se notificó este resultado a su Departamento de Salud Pública.

Si se siente bien y no tiene fiebre ni tos, puede reanudar sus actividades normales siguiendo las recomendaciones de su Departamento de Salud local y estatal con respecto a las órdenes de Quedarse en Casa o Refugio Designado.

Independientemente de su resultado, aún es importante que tome las siguientes medidas de cuidado en su hogar:

- Lávese bien las manos frecuentemente con agua y jabón durante al menos 20 segundos. Si no dispone de agua y jabón, use un desinfectante para manos que contenga al menos el 60% de alcohol. Evite tocarse los ojos, la nariz y la boca con las manos sin lavar.
- Para toser o estornudar, cúbrase la boca y la nariz con un pañuelo de papel y deséchelo inmediatamente. Si no dispone de pañuelos de papel, tosa/estornude en el pliegue del codo, no en las manos. Lávese bien las manos con agua y jabón inmediatamente después.
- Evite compartir utensilios, toallas, ropa de cama, ropa u otros artículos. Lave bien los artículos con agua y jabón.
- Practique el distanciamiento físico. Esto incluye evitar los lugares públicos concurridos donde podría haber un contacto estrecho con otras personas. Mantenga una distancia de 6 pies (2 metros) de otras personas, cuando sea posible. Evite el contacto con personas que estén enfermas.
- Use una mascarilla o un barbijo de tela casero cuando se encuentre en las siguientes situaciones:
  o Dentro de, o en la cola para ingresar en, cualquier lugar público cerrado
  o Usando el transporte público, un taxi, un servicio de automóvil privado o vehículo de viajes compartidos
  o Al aire libre sin poder mantener una distancia física de 6 pies (2 metros) de otras personas
- Use detergente de uso doméstico y agua para limpiar las superficies de contacto frecuente como encimeras, interruptores de luz, barandas, teléfonos, teclados, inodoros, canillas y picaportes. Las superficies sucias se deben limpiar, luego desinfectar con un desinfectante de uso doméstico común.
- Abra las ventanas y use un ventilador (si es posible) en espacios compartidos para que haya una buena circulación de aire.
- Esté alerta a los síntomas. Esté atento a la aparición de fiebre, tos, dificultad para respirar (disnea) u otros síntomas de COVID-19. Si aparecen síntomas, tómese la temperatura. Si aparecen síntomas, siga las recomendaciones de los CDC.
Si recientemente estuvo expuesto a alguien con COVID-19, debería quedarse en casa y ponerse en cuarentena (aislarse de los demás) durante 14 días, contados desde el último día en que estuvo posiblemente expuesto a la COVID-19. Debería seguir controlando los síntomas hasta 14 días después de su última posible exposición. Si tiene más preguntas, comuníquese con su proveedor de atención primaria. Ha sido un enorme privilegio ayudarle con su atención de la salud.
To: [Redacted]
DOB: [Redacted]

The result of your COVID-19 Nasal RT-PCR test that was administered on 11/05/2020 is Negative.

Your Public Health Department has been notified of this result as required by law.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to ‘Stay at Home’ or ‘Shelter in Place’ orders.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use cloth face coverings when you are:
  - Inside of, or in line to enter, any indoor public place
  - Using public transportation, a taxi, private car service, or ride-sharing vehicle
  - Outside and unable to physical distance 6 feet (2 meters) away from others
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.
- Open windows and use a fan (if possible) in shared spaces for good airflow.
- Be alert for symptoms. Watch for fever, cough, shortness of breath, or other symptoms of COVID-19. Take your temperature if symptoms develop. Follow CDC guidance if symptoms develop.

If you were recently exposed to someone with COVID-19, you should still stay at home and self-quarantine (separate yourself from others) for 14 days, starting from the most recent day that you were possibly exposed to COVID-19. You should continue to monitor for symptoms for up to 14 days after your last possible exposure. If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
Para: [nombre]
Fecha de nacimiento: [fecha]

El resultado de su RT-PCR prueba de COVID-19 Nasal, realizada en 11/05/2020 es Negative.

Según lo exigido por la ley, se notificó este resultado a su Departamento de Salud Pública.

Si se siente bien y no tiene fiebre ni tos, puede reanudar sus actividades normales siguiendo las recomendaciones de su Departamento de Salud local y estatal con respecto a las órdenes de Quedarse en Casa o Refugio Designado.

Independientemente de su resultado, aún es importante que tome las siguientes medidas de cuidado en su hogar:

- Lávese bien las manos frecuentemente con agua y jabón durante al menos 20 segundos. Si no dispone de agua y jabón, use un desinfectante para manos que contenga al menos el 60% de alcohol. Evite tocarse los ojos, la nariz y la boca con las manos sin lavar.
- Para toser o estornudar, cúbrase la boca y la nariz con un pañuelo de papel y deséchelo inmediatamente. Si no dispone de pañuelos de papel, tosa/estornude en el pliegue del codo, no en las manos. Lávese bien las manos con agua y jabón inmediatamente después.
- Evite compartir utensilios, toallas, ropa de cama, ropa u otros artículos. Lave bien los artículos con agua y jabón.
- Practique el distanciamiento físico. Esto incluye evitar los lugares públicos concurridos donde podría haber un contacto estrecho con otras personas. Mantenga una distancia de 6 pies (2 metros) de otras personas, cuando sea posible. Evite el contacto con personas que estén enfermas.
- Use una mascarilla o un barbijo de tela casero cuando se encuentre en las siguientes situaciones:
  - Dentro de, o en la cola para ingresar en, cualquier lugar público cerrado
  - Usando el transporte público, un taxi, un servicio de automóvil privado o vehículo de viajes compartidos
  - Al aire libre sin poder mantener una distancia física de 6 pies (2 metros) de otras personas
- Use detergente de uso doméstico y agua para limpiar las superficies de contacto frecuente como encimeras, interruptores de luz, barandas, teléfonos, teclados, inodoros, canillas y picaportes. Las superficies sucias se deben limpiar, luego desinfectar con un desinfectante de uso doméstico común.
- Abra las ventanas y use un ventilador (si es posible) en espacios compartidos para que haya una buena circulación de aire.
- Esté alerta a los síntomas. Esté atento a la aparición de fiebre, tos, dificultad para respirar (disnea) u otros síntomas de COVID-19. Si aparecen síntomas, tómese la temperatura. Si aparecen síntomas, siga las recomendaciones de los CDC.
Si recientemente estuvo expuesto a alguien con COVID-19, debería quedarse en casa y ponerse en cuarentena (aislarse de los demás) durante 14 días, contados desde el último día en que estuvo posiblemente expuesto a la COVID-19. Debería seguir controlando los síntomas hasta 14 días después de su última posible exposición. Si tiene más preguntas, comuníquese con su proveedor de atención primaria. Ha sido un enorme privilegio ayudarle con su atención de la salud.
Patient Name: [Redacted]  
DOB: [Redacted]  
Patient MRN: [Redacted]  
Phone: (559) 972-7393  
Hospital Sample ID Number: [Redacted]  

Ordering Provider Name: Teske, Milton  
Location: Kings County Public Health Laboratory  
Sample ID: [Redacted]

Coronavirus Disease 2019 PCR-Upper Respiratory  
Collected: 8/24/2020 1:47 PM  
Received: 8/24/2020 4:14 PM  
Approval Date: 8/25/2020 12:45 PM

TaqPath COVID-19 Combo Kit Result  
SARS-CoV-2 Not Detected


The tests performed at the TCPHL have been made available by the FDA under an Emergency Use Authorization (EUA). Their use within the United States is limited to qualified laboratories, including the Tulare County Public Health Lab, with training, facilities and equipment appropriate for specimen handling, testing and interpretation of the results of these real-time RT-PCR assays. The EUA for these tests are supported by the Secretary of Health and Human Services' declaration that circumstances exist to justify the use of in-vitro diagnostics under EUA for the detection and/or diagnosis of SARS-CoV-2. This EUA will remain in effect for the duration of the SARS-CoV-2 emergency, unless terminated or revoked by the FDA. Results should be considered in the context of clinical observations and epidemiological data.

A laboratory result of “Not Detected” does not conclusively rule out disease. Tests on additional samples may be pending at the Tulare County Public Health Laboratory (TCPHL). Please review results as soon as they become available.

Reference Range  
Not Detected

Reporting Laboratories: Tulare Public Health Lab (CLIA ID: 05D0007647)  
Lab Director: Miriam Lachica, MA  
1062 South "K" Street, Tulare, CA 93274  
Ph: 559.685.5750

Report Status: END OF REPORT (Final)
To: [redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tablespops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to ‘Stay at Home’ or ‘Shelter in Place’ orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
Patient Name: [Redacted]
Ordering Provider Name: Teske, Milton
DOB: [Redacted]
Location: Kings County Public Health Laboratory
Phone: (559) 972-7393

Hospital Sample ID Number: [Redacted]

Coronavirus Disease 2019 PCR-Upper Respiratory

| Collected: 8/24/2020 1:49 PM | Received: 8/24/2020 4:12 PM | Approval Date: 8/25/2020 12:45 PM |

TaqPath COVID-19 Combo Kit Result
SARS-CoV-2 Not Detected

Reference Range
Not Detected

The tests performed at the TCPHL have been made available by the FDA under an Emergency Use Authorization (EUA). These tests are specific for SARS-CoV-2 and are supported by the Secretary of Health and Human Services' declaration that circumstances exist to justify the use of in-vitro diagnostics under EUA for the detection and/or diagnosis of SARS-CoV-2. This EUA will remain in effect for the duration of the SARS-CoV-2 emergency, unless terminated or revoked by the FDA. Results should be considered in the context of clinical observations and epidemiological data.

A laboratory result of "Not Detected" does not conclusively rule out disease. Tests on additional samples may be pending at the Tulare County Public Health Laboratory (TCPHL). Please review results as soon as they become available.

Reporting Laboratories: Tulare Public Health Lab (CLIA ID: 05D0007847)
Lab Director: Miriam Lachica, MA
1062 South "K" Street, Tulare, CA 93274
Ph: 559.685.5750

Report Status: END OF REPORT (Final)
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to ‘Stay at Home’ or ‘Shelter in Place’ orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
<table>
<thead>
<tr>
<th>Patient Name:</th>
<th>Ordering Provider Name: Teske, Milton</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOB:</td>
<td>Location: Kings County Public Health Laboratory</td>
</tr>
<tr>
<td>Patient MRN:</td>
<td>Phone: (559) 972-7393</td>
</tr>
<tr>
<td>Hospital Sample ID Number</td>
<td>Sample ID:</td>
</tr>
</tbody>
</table>

### Coronavirus Disease 2019 PCR-Upper Respiratory

<table>
<thead>
<tr>
<th>Collected: 8/24/2020 1:51 PM</th>
<th>Received: 8/24/2020 4:14 PM</th>
<th>Approval Date: 8/25/2020 12:45 PM</th>
</tr>
</thead>
</table>

**TagPath COVID-19 Combo Kit Result**: SARS-CoV-2 Not Detected


The tests performed at the TCPHL have been made available by the FDA under an Emergency Use Authorization (EUA). Their use within the United States is limited to qualified laboratories, including the Tulare County Public Health Lab, with training, facilities and equipment appropriate for specimen handling, testing and interpretation of the results of these real-time RT-PCR assays. The EUA for these tests are supported by the Secretary of Health and Human Services' declaration that circumstances exist to justify the use of in-vitro diagnostics under EUA for the detection and diagnosis of SARS-CoV-2. This EUA will remain in effect for the duration of the SARS-CoV-2 emergency, unless terminated or revoked by the FDA. Results should be considered in the context of clinical observations and epidemiological data.

A laboratory result of "Not Detected" does not conclusively rule out disease. Tests on additional samples may be pending at the Tulare County Public Health Laboratory (TCPHL). Please review results as soon as they become available.

**Reference Range**: Not Detected

**Reporting Laboratories**: Tulare Public Health Lab (CLIA ID: 05D00567647)
Lab Director: Miriam Lachica, MA
1062 South "K" Street, Tulare, CA 93274
Ph: 559.685.5750

**Report Status**: END OF REPORT (Final)
To: 

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to ‘Stay at Home’ or ‘Shelter in Place’ orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To:

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to ‘Stay at Home’ or ‘Shelter in Place’ orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tablespops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: 

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
Patient Name: [REDACTED]  
DOB: [REDACTED]  
Patient MRN: [REDACTED]  
Phone: (559) 972-7363  
Hospital Sample ID Number: [REDACTED]

Coronavirus Disease 2019 PCR-Upper Respiratory

Collected: 8/24/2020 1:55 PM  
Received: 8/24/2020 4:13 PM  
Approval Date: 8/25/2020 12:45 PM

TaqPath COVID-19 Combo Kit Result  
SARS-CoV-2 Not Detected


The tests performed at the TCPHL have been made available by the FDA under an Emergency Use Authorization (EUA). Their use within the United States is limited to qualified laboratories, including the Tulare County Public Health Lab, with training, facilities and equipment appropriate for specimen handling, testing and interpretation of the results of these real-time RT-PCR assays. The EUA for these tests are supported by the Secretary of Health and Human Services' declaration that circumstances exist to justify the use of in-vitro diagnostics under EUA for the detection and/or diagnosis of SARS-CoV-2. This EUA will remain in effect for the duration of the SARS-CoV-2 emergency, unless terminated or revoked by the FDA. Results should be considered in the context of clinical observations and epidemiological data.

A laboratory result of "Not Detected" does not conclusively rule out disease. Tests on additional samples may be pending at the Tulare County Public Health Laboratory (TCPHL). Please review results as soon as they become available.

Reference Range

Not Detected

Reporting Laboratories: Tulare Public Health Lab (CLIA ID: 05D0667647)  
Lab Director: Miriam Luchica, MA  
1062 South "K" Street, Tulare, CA 93274  
Ph: 559.685.5750

Report Status: END OF REPORT (Final)
To: [REDACTED]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to ‘Stay at Home’ or ‘Shelter in Place’ orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
Patient Name: 
DOB: 
Patient MRN: 
Phone: 
Hospital Sample ID Number: 

Coronavirus Disease 2019 PCR-Upper Respiratory
Collected: 8/24/2020 1:53 PM  Received: 8/24/2020 4:15 PM  Approval Date: 8/25/2020 12:45 PM

TaqPath COVID-19 Combo Kit Result
SARS-CoV-2 Not Detected

The factsheets for healthcare providers and patients are available at: https://www.meridianhhs.org/our-services/pathogen-detection-solutions/taqpath-covid-19-diagnostic-kit.html

The tests performed at the TCPHL have been made available by the FDA under an Emergency Use Authorization (EUA). Their use within the United States is limited to qualified laboratories, including the Tulare County Public Health Lab, with training, facilities and equipment appropriate for specimen handling, testing and interpretation of the results of these real-time RT-PCR assays. The EUA for these tests are supported by the Secretary of Health and Human Services' declaration that circumstances exist to justify the use of in-vitro diagnostics under EUA for the detection and/or diagnosis of SARS-CoV-2. This EUA will remain in effect for the duration of the SARS-CoV-2 emergency, unless terminated or revoked by the FDA. Results should be considered in the context of clinical observations and epidemiological data.

A laboratory result of "Not Detected" does not conclusively rule out disease. Tests on additional samples may be pending at the Tulare County Public Health Laboratory (TCPHL). Please review results as soon as they become available.

Reference Range
Not Detected

Reporting Laboratories: Tulare Public Health Lab (CLIA ID: 05D0967647)
Lab Director: Miriam Lachica, MA
1082 South "K" Street, Tulare, CA 93274
Ph: 559.685.5750

Report Status: END OF REPORT (Final)
To: [Recipient Name]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Name]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to ‘Stay at Home’ or ‘Shelter in Place’ orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to ‘Stay at Home’ or ‘Shelter in Place’ orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to ‘Stay at Home’ or ‘Shelter in Place’ orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Name]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to ‘Stay at Home’ or ‘Shelter in Place’ orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [Redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
To: [redacted]

Your COVID-19 test result is Negative.

If you feel well and do not have a fever or cough, you may go about your normal activity abiding by your state and local health department recommendation in regards to 'Stay at Home' or 'Shelter in Place' orders. There are times when a second test is needed. Contact your primary health care provider or local Public Health Department if you have a question about re-testing.

Regardless of your result, it is still important for you to take the following actions for care at home:

- Wash hands thoroughly and frequently with soap and water for at least 20 seconds. If soap and water are not readily available, use an alcohol based hand sanitizer that contains at least 60% alcohol. Avoid touching eyes, nose, and mouth with unwashed hands.
- To cough or sneeze, cover mouth and nose with a tissue and immediately dispose of it. If no tissue is available, cough/sneeze into the inside of elbow, not hands. Wash hands thoroughly with soap and water immediately following.
- Avoid sharing eating utensils, towels, linens, clothes or other items. Wash items thoroughly with soap and water.
- Practice physical distancing. This includes avoiding crowded public places where close contact with others may occur. Maintain distance of 6 feet (2 meters) from others, when possible. Avoid contact with people who are sick.
- Use household detergent and water to clean frequently touched surfaces such as tabletops, light switches, handles, phones, keyboards, toilets, faucets, and doorknobs. Dirty surfaces should be cleaned, then disinfected using common household disinfectant.

If you have additional questions please contact your primary provider. It has been our great privilege in assisting you in your healthcare.
SARS-CoV-2, NAA

Testing was performed using the cobas(R) SARS-CoV-2 test. This test was developed and its performance characteristics determined by LabCorp Laboratories. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Patient Details
DOB: [redacted]
Age (y/m/d): [redacted]
Gender: [redacted]
Patient ID: [redacted]

Specimen Details
Date collected: 08/18/2020 10:15 Local
Date received: 08/18/2020
Date entered: 08/18/2020
Date reported: 08/20/2020 13:09 ET

Physician Details
Ordering: [redacted]
Referring: [redacted]
ID: [redacted]
NPI: [redacted]

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Testing was performed using the Abbott RealTime SARS-CoV-2 assay. This test was developed and its performance characteristics determined by LabCorp Laboratories. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

Please note
The date and/or time of collection was not indicated on the requisition as required by state and federal law. The date of receipt of the specimen was used as the collection date if not supplied.

One Specimen Identifier
The specimen received included only one patient identifier on the primary collection container. Our laboratory accrediting agency states "All primary specimen containers must be labeled with 2 identifiers at the time of collection."

01 L9 Monogram Biosciences Inc
345 Oyster Point Blvd, S San Francisco, CA 94080-1913
Dir: Weidong Huang, MD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 800-777-0177
Patient Details
DOB: [DOB]
Age(y/m/d): [Age]
Gender: [Gender]
Patient ID: [Patient ID]

Specimen Details
Date collected: 08/18/2020 12:00 Local
Date received: 08/19/2020
Date entered: 08/19/2020
Date reported: 08/20/2020 11:09 ET

Physician Details
Ordering: [Ordering]
Referring: [Referring]
ID: [ID]
NPI: [NPI]

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Testing was performed using the Aptima SARS-CoV-2 assay. This test was developed and its performance characteristics determined by LabCorp Laboratories. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient’s recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 858-668-3700
Patient Report

Specimen ID: [redacted]
Control ID: [redacted]

Acct #: 04122570
Phone: (559) 852-2927
Rte: 00

Kings Co Adult Jail
1570 Kings Co Drive
Hanford CA 93230

Patient Details
DOB: [redacted]
Age (y/m/d): [redacted]
Gender: [redacted]
Patient ID: [redacted]

Specimen Details
Date collected: 09/11/2020 1000 Local
Date received: 09/15/2020
Date entered: 09/15/2020
Date reported: 09/16/2020 0816 ET

Physician Details
Ordering: [redacted]
Referring: [redacted]
ID: [redacted]
NPI: [redacted]

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b) (1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01  SEQCO  Integrated Genetics Sequenom
     3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-521-7266
Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Detected</td>
<td>Abnormal</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Test SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>Test Description</th>
<th>Result</th>
<th>Flag</th>
<th>Units</th>
<th>Reference Interval</th>
<th>Lab</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td>SEQCO</td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Specimen ID: [redacted]
Control ID: [redacted]

Patient Details
DOB: [redacted]
Age(y/m/d): [redacted]
Gender: [redacted]
Patient ID: [redacted]

Specimen Details
Date collected: 10/08/2020 0000 Local
Date received: 10/09/2020
Date entered: 10/09/2020
Date reported: 10/10/2020 0910 ET

Physician Details
Ordering: S GUSTAVESO
Referring: ID: [redacted]
NPI: 1598777559

General Comments & Additional Information
Alternate Control Number: [redacted]
Alternate Patient ID: Not Provided

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
SARS-CoV-2, NAA

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Patient Details
DOB: [Redacted]
Age(y/m/d): [Redacted]
Gender: [Redacted]
Patient ID: [Redacted]

Specimen Details
Date collected: 10/08/2020 1300 Local
Date received: 10/09/2020
Date entered: 10/09/2020
Date reported: 10/10/2020 0910 ET

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

Dir: Phillip Cacheris, MDPhD
3595 John Hopkins Court, San Diego, CA 92121-1121
For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7286
<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Specimen ID: [REDACTED]  
Control ID: [REDACTED]

Patient Details
DOB: [REDACTED]  
Age(y/m/d): [REDACTED]  
Gender: [REDACTED]  
Patient ID: [REDACTED]

Specimen Details
Date collected: 10/08/2020 1305 Local  
Date received: 10/09/2020  
Date entered: 10/09/2020  
Date reported: 10/10/2020 0910 ET

Physician Details
Ordering: [REDACTED]  
Referring: [REDACTED]  
ID:  
NPI: 1598777559

General Comments & Additional Information
Alternate Control Number: [REDACTED]  
Alternate Patient ID: Not Provided

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQUO Integrated Genetics Sequenom  
Dir: Phillip Cacheris, MDPhD  
3595 John Hopkins Court, San Diego, CA 92121-1121  
For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Details**

DOB:  
Age (y/m/d):  
Gender:  
Patient ID:  

**Specimen Details**

Date collected: 10/08/2020 1305 Local
Date received: 10/09/2020
Date entered: 10/09/2020
Date reported: 10/10/2020 0910 ET

**Physician Details**

Ordering: S Gustaveso
Referring: ID: NPI:

**Ordered Items**

**Tests** | **Result** | **Flag** | **Units** | **Reference Interval** | **Lab**  
--- | --- | --- | --- | --- | ---  
SARS-CoV-2, NAA | Not Detected | Not Detected | 01

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
Patient Details
DOB: 
Age(y/m/d): 
Gender: 
Patient ID: 

Specimen Details
Date collected: 10/23/2020 1530 Local
Date received: 10/24/2020
Date entered: 10/24/2020
Date reported: 10/25/2020 0707 ET

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Ordered Items**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Patient Details
- DOB: [redacted]
- Age/m/d: [redacted]
- Gender: [redacted]
- Patient ID: [redacted]

Specimen Details
- Date collected: 10/23/2020 1545 Local
- Date received: 10/24/2020
- Date entered: 10/24/2020
- Date reported: 10/25/2020 0707 ET

Physician Details
- Ordering: [redacted]
- Referring: [redacted]
- ID: GUSTAVESON
- NPI: [redacted]

General Comments & Additional Information
- Total Volume: Not Provided
- Fasting: No

Ordered Items
- SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Details**

- **DOB:**
- **Age(y/m/d):**
- **Gender:**
- **Patient ID:**

**Specimen Details**

- **Date collected:** 10/23/2020 1530 Local
- **Date received:** 10/24/2020
- **Date entered:** 10/24/2020
- **Date reported:** 10/25/2020 0707 ET

**Physician Details**

- **Ordering:**
- **Referring:**
- **ID:** GUSTAVESON
- **NPI:**

**General Comments & Additional Information**

- **Total Volume:** Not Provided
- **Fasting:** No

**Ordered Items**

SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

<table>
<thead>
<tr>
<th>01</th>
<th>SEQCO Integrated Genetics Sequenom</th>
<th>Dir: Phillip Cacheris, MDPhD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3695 John Hopkins Court, San Diego, CA 92121-1121</td>
<td>For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7236</td>
</tr>
</tbody>
</table>

© 1995-2020 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00
### Patient Details
- **DOB:** [redacted]
- **Age:** [redacted]
- **Gender:** [redacted]
- **Patient ID:** [redacted]

### Specimen Details
- **Date collected:** 10/23/2020 1535 Local
- **Date received:** 10/24/2020
- **Date entered:** 10/24/2020
- **Date reported:** 10/25/2020 0707 ET

### Physician Details
- **Ordering:** [redacted]
- **Referring:** [redacted]
- **ID:** GUSTAVESON
- **NPI:** [redacted]

### Ordered Items
<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
</table>
| SARS-CoV-2, NAA | Not Detected | Not Detected | 01 | SEQCO Integrated Genetics Sequenom 3595 John Hopkins Court, San Diego, CA 92121-1121

---

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
SARS-CoV-2, NAA

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Patient Details
DOB: [redacted]
Age(y/m/d): [redacted]
Gender: [redacted]
Patient ID: [redacted]

Specimen Details
Date collected: 10/23/2020 1530 Local
Date received: 10/24/2020
Date entered: 10/24/2020
Date reported: 10/25/2020 0707 ET

Physician Details
Ordering: GUSTAVESON
Referring: [redacted]
ID: [redacted]
NPI: [redacted]

General Comments & Additional Information
Total Volume: Not Provided
Fasting: No

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td></td>
<td>Not Detected</td>
<td>01</td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01  SEQCO  Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

Dir: Phillip Cacheris, MDPhD

Date Issued: 10/26/20 1112 ET

© 1995-2020 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
SARS-CoV-2, NAA

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
### Patient Details

DOB: [Redacted]
Age (y/m/d): [Redacted]
Gender: [Redacted]
Patient ID: [Redacted]

### Specimen Details

- **Date collected:** 10/27/2020 1602 Local
- **Date received:** 10/28/2020
- **Date entered:** 10/28/2020
- **Date reported:** 10/29/2020 2007 ET

### Ordered Items

- **SARS-CoV-2, NAA**

### Order Details

- **Ordering:** X WESTON
- **ID:** [Redacted]
- **NPI:** [Redacted]

### Tests

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
SARS-CoV-2, NAA

Not Detected

Not Detected

01

SEQCO Integrated Genetics Sequenom
3995 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

Dir: Phillip Cacheris, MDPhD

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Specimen Details

- Date collected: 11/05/2020 1200 Local
- Date received: 11/06/2020
- Date entered: 11/06/2020
- Date reported: 11/07/2020 0709 ET

Ordered Items

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

Dir: Phillip Cacheris, MDPhD
SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 677-821-7266
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Details**

- **DOB:**
- **Age (y/m/d):**
- **Gender:**
- **Patient ID:**

**Specimen Details**

- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

**Physician Details**

- **Ordering:**
- **Referring:**
- **ID:**
- **NPI:**

### Ordered Items

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>REFERENCE INTERVAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>01</td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

**Final Report**

SEQCO Integrated Genetics Sequenom

3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 617-821-7266

Dir: Phillip Cacheris, MDPhD

© 1995-2020 Laboratory Corporation of America® Holdings All Rights Reserved - Enterprise Report Version: 1.00
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Patient Details
DOB: [redacted]
Age(y/m/d): [redacted]
Gender: [redacted]
Patient ID: [redacted]

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD
For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
### Patient Details

**DOB:**

**Age/y/m/d:**

**Gender:**

**Patient ID:**

### Specimen Details

**Date collected:** 11/05/2020 1200 Local

**Date received:** 11/06/2020

**Date entered:** 11/06/2020

**Date reported:** 11/07/2020 0709 ET

### Ordered Items

**SARS-CoV-2, NAA**

### Physician Details

**Ordering:** LIBERSTEI

**Referring:**

**ID:**

**NPI:**

### Tests

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Report**

**Specimen ID:** [Redacted]

**Control ID:** [Redacted]

**Acct #:** 04122570  **Phone:** (559) 852-2927  **Rte:** 00

Kings Co Adult Jail
1570 Kings Co Drive
Hanford CA 93230

**Patient Details**

DOB: [Redacted]
Age(y/m/d): [Redacted]
Gender: [Redacted]
Patient ID: [Redacted]

**Specimen Details**

Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

**Physician Details**

Ordering: [Redacted]
Referring: [Redacted]
ID: [Redacted]
NPI: [Redacted]

**General Comments & Additional Information**

Total Volume: Not Provided  
Fasting: No

**Ordered Items**

SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

**01 SEQCO Integrated Genetics Sequenom**

3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

---

**Date Issued:** 11/09/20 1228 ET  
**FINAL REPORT**  
**Page 1 of 1**

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 858-668-3700

© 1995-2020 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00
Patient Details
DOB: [redacted]
Age(y/m/d): [redacted]
Gender: [redacted]
Patient ID: [redacted]

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Physician Details
Ordering: [redacted]
Referring: [redacted]
ID: [redacted]
NPI: [redacted]

General Comments & Additional Information
Total Volume: Not Provided
Fasting: No

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td>SEQCO</td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121
For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
**Patient Details**

<table>
<thead>
<tr>
<th>DOB</th>
<th>Age(y/m/d)</th>
<th>Gender</th>
<th>Patient ID</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Specimen Details**

<table>
<thead>
<tr>
<th>Date collected</th>
<th>Date received</th>
<th>Date entered</th>
<th>Date reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/05/2020 12:00 Local</td>
<td>11/06/2020</td>
<td>11/06/2020</td>
<td>11/07/2020 07:09 ET</td>
</tr>
</tbody>
</table>

**Physician Details**

<table>
<thead>
<tr>
<th>Ordering</th>
<th>Referring</th>
<th>ID</th>
<th>NPI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Ordered Items**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient’s recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQCO Integrated Genetics Sequenom 3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 677-821-7266
**Patient Report**

**Specimen ID:** [redacted]
**Control ID:** [redacted]

**Acct #:** 04122570  
**Phone:** (559) 852-2927  
**Rte:** 00

Kings Co Adult Jail  
1570 Kings Co Drive  
Hanford CA 93230

---

**Patient Details**

<table>
<thead>
<tr>
<th>Item</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOB</td>
<td>[redacted]</td>
</tr>
<tr>
<td>Age(y/m/d)</td>
<td>[redacted]</td>
</tr>
<tr>
<td>Gender</td>
<td>[redacted]</td>
</tr>
<tr>
<td>Patient ID</td>
<td>[redacted]</td>
</tr>
</tbody>
</table>

---

**Specimen Details**

<table>
<thead>
<tr>
<th>Item</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date collected</td>
<td>11/05/2020 1200 Local</td>
</tr>
<tr>
<td>Date received</td>
<td>11/06/2020</td>
</tr>
<tr>
<td>Date entered</td>
<td>11/06/2020</td>
</tr>
<tr>
<td>Date reported</td>
<td>11/07/2020 0709 ET</td>
</tr>
</tbody>
</table>

---

**Physician Details**

<table>
<thead>
<tr>
<th>Item</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordering</td>
<td>LIBERSTEI</td>
</tr>
<tr>
<td>Referring</td>
<td>LIBERSTEIN</td>
</tr>
</tbody>
</table>

---

**Ordered Items**

<table>
<thead>
<tr>
<th>Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

---

**Laboratory Information**

<table>
<thead>
<tr>
<th>Item</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Branch</td>
<td>800-888-1113</td>
</tr>
<tr>
<td>Lab</td>
<td>877-821-7266</td>
</tr>
<tr>
<td>Dir</td>
<td>Phillip Cacheris, MDPhD</td>
</tr>
</tbody>
</table>

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

---

© 1995-2020 Laboratory Corporation of America® Holdings  
All Rights Reserved - Enterprise Report Version: 1.00
Patient Details
DOB: 
Age(y/m/d): 
Gender: 
Patient ID: 

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Physician Details
Ordering: LIBERSTEI
Referring: ID: LIBERSTEIN
NPI: 

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Details**

- **DOB:** 
- **Age(y/m/d):** 
- **Gender:** 
- **Patient ID:**

**Specimen Details**

- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

**Physician Details**

- **Ordering:** Referring:
- **ID:** NPI:

**Ordered Items**

- **SARS-CoV-2, NAA**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

**01 SEQCO Integrated Genetics Sequenom**

Dir: Phillip Cacheris, MDPhD

3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-621-7266
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Patient Report

Specimen ID: [redacted]
Control ID: [redacted]

Kings Co Adult Jail
1570 Kings Co Drive
Hanford CA 93230

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Physician Details
Ordering: Referring:
ID:
NPI:

Patient Details
DOB: [redacted]
Age(y/m/d): [redacted]
Gender: [redacted]
Patient ID: [redacted]

General Comments & Additional Information
Total Volume: Not Provided
Fasting: No

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQUO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

Date Issued: 11/09/20 1228 ET
### Patient Details
- **DOB:**
- **Age (y/m/d):**
- **Gender:**
- **Patient ID:**

### Specimen Details
- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

### Ordered Items
- **SARS-CoV-2, NAA**

### Tests Details

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Details**

- **DOB**: [redacted]
- **Age(y/m/d)**: [redacted]
- **Gender**: [redacted]
- **Patient ID**: [redacted]

**Specimen Details**

- **Date collected**: 11/05/2020 1200 Local
- **Date received**: 11/06/2020
- **Date entered**: 11/06/2020
- **Date reported**: 11/07/2020 0709 ET

**Ordered Items**

- **SARS-CoV-2, NAA**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01  SEQCO Integrated Genetics Sequenom

3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

Dir: Phillip Cacheris, MDPhD
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Report**

**Specimen ID:** [redacted]

**Control ID:** [redacted]

**Acct #:** 04122570

**Phone:** (559) 852-2927

**Rte:** 00

Kings Co Adult Jail
1570 Kings Co Drive
Hanford CA 93230

---

**Patient Details**

- **DOB:** [redacted]
- **Age (y/m/d):** [redacted]
- **Gender:** [redacted]
- **Patient ID:** [redacted]

---

**Specimen Details**

- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

---

**Physician Details**

- **Ordering:** [redacted]
- **Referring:** [redacted]
- **ID:** [redacted]
- **NPI:** [redacted]

---

**Ordered Items**

- SARS-CoV-2, NAA

---

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

---

**01 SEQCO Integrated Genetics Sequenom**

3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

---

© 1995-2020 Laboratory Corporation of America® Holdings

All Rights Reserved - Enterprise Report Version: 1.00
**Patient Details**
- **DOB:**
- **Age (y/m/d):**
- **Gender:**
- **Patient ID:**

**Specimen Details**
- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

**Ordered Items**
- **SARS-CoV-2, NAA**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Patient Details
DOB: 
Age(y/m/d): 
Gender: 
Patient ID: 

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7286
<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQCO Integrated Genetics Sequenom

For inquiries, the physician may contact Branch: 800-866-1113 Lab: 877-821-7266
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient’s recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
## Ordered Items

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td>3595 John Hopkins Court, San Diego, CA 92121-1121</td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Report**

Specimen ID: [Redacted]
Control ID: [Redacted]

**Kings Co Adult Jail**
1570 Kings Co Drive
Hanford CA 93230

<table>
<thead>
<tr>
<th><strong>Patient Details</strong></th>
<th><strong>Specimen Details</strong></th>
<th><strong>Physician Details</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DOB:</strong> [Redacted]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age(y/m/d): [Redacted]</td>
<td>Date collected: 11/05/2020 1200 Local</td>
<td>Ordering: LIBERSTEI</td>
</tr>
<tr>
<td>Gender: [Redacted]</td>
<td>Date received: 11/06/2020</td>
<td>Referring: ID:</td>
</tr>
<tr>
<td>Patient ID: [Redacted]</td>
<td>Date entered: 11/06/2020</td>
<td>NPI:</td>
</tr>
<tr>
<td></td>
<td>Date reported: 11/07/2020 0709 ET</td>
<td></td>
</tr>
</tbody>
</table>

**General Comments & Additional Information**
Total Volume: Not Provided
Fasting: No

**Ordered Items**
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQC0 Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7286

Date Issued: 11/09/20 1114 ET

**FINAL REPORT**

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 858-668-3700

© 1995-2020 Laboratory Corporation of America Holdings
All Rights Reserved - Enterprise Report Version: 1.00
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Report**

**Specimen ID:**

**Control ID:**

**Acct #:** 04122570

**Kings Co Adult Jail**

1570 Kings Co Drive

Hanford CA 93230

---

**Patient Details**

DOB:

Age (y/m/d): 

Gender:

Patient ID:

---

**Specimen Details**

Date collected: 11/05/2020 1200 Local

Date received: 11/06/2020

Date entered: 11/06/2020

Date reported: 11/07/2020 0709 ET

---

**Ordered Items**

SARS-CoV-2, NAA

---

### TESTS | RESULT | FLAG | UNITS | REFERENCE INTERVAL | LAB
--- | --- | --- | --- | --- | ---

SARS-CoV-2, NAA | Not Detected | Not Detected | | 01 | 

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

---

**Physician Details**

Ordering: LIBERSTI

Referring:

ID: 

NPI: 

---

**Test Results**

01 SEQCO Integrated Genetics Sequenom

3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

---

**Date Issued:** 11/09/20 1114 ET

**FINAL REPORT**

© 1995-2020 Laboratory Corporation of America® Holdings

All Rights Reserved - Enterprise Report Version: 1.00

---

This document contains private and confidential health information protected by state and federal law.

If you have received this document in error, please call 858-668-3700
**Patient Report**

**Specimen ID:** [redacted]

**Control ID:** [redacted]

**Acct #:** 04122570  
**Phone:** (559) 852-2927  
**Rte:** 00

Kings Co Adult Jail  
1570 Kings Co Drive  
Hanford CA 93230

**Patient Details**

DOB: [redacted]  
Age(y/m/d): [redacted]  
Gender: [redacted]  
Patient ID: [redacted]

**Specimen Details**

**Date collected:** 11/05/2020 1200 Local  
**Date received:** 11/06/2020  
**Date entered:** 11/06/2020  
**Date reported:** 11/07/2020 0709 ET

**Physician Details**

Ordering: LIBERSTEI  
Referring:

**Ordered Items**

SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01  SEQCO Integrated Genetics Sequenom  
3595 John Hopkins Court, San Diego, CA 92121-1121  
Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

© 1995-2020 Laboratory Corporation of America Holdings  
All Rights Reserved - Enterprise Report Version: 1.00

Date Issued: 11/09/20 1114 ET  
FINAL REPORT  
Page 1 of 1

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 858-668-3700
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

For inquiries, the physician may contact Branch: 800-868-1113 Lab: 877-821-7266
<table>
<thead>
<tr>
<th>Tests</th>
<th>Result</th>
<th>Flag</th>
<th>Units</th>
<th>Reference Interval</th>
<th>Lab</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td>SEQCO</td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Details**

DOB: 
Age(y/m/d): 
Gender: 
Patient ID: 

**Specimen Details**

Date collected: 11/05/2020 1200 Local  
Date received: 11/06/2020 
Date entered: 11/06/2020  
Date reported: 11/07/2020 0813 ET

**Ordered Items**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01  SEQUO Integrated Genetics Sequenom  
3595 John Hopkins Court, San Diego, CA 92121-1121  
Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Patient Details
DOB: 11/05/2020
Age(y/m/d): 30
Gender: M
Patient ID: 04122570

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Physician Details
Ordering: LIBERSTEI
Referring:
ID:
NPI:

General Comments & Additional Information
Total Volume: Not Provided
Fasting: No

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121
Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

01 SEQCO Integrated Genetics Sequenom
3555 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
**Patient Details**
- **DOB:** [redacted]
- **Age:** [redacted]
- **Gender:** [redacted]
- **Patient ID:** [redacted]

**Specimen Details**
- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

**Physician Details**
- **Ordering:** [redacted]
- **Referring:** [redacted]
- **ID:** [redacted]
- **NPI:** [redacted]

**Ordered Items**
- **SARS-CoV-2, NAA**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Details**
- **DOB:** [redacted]
- **Age:** [redacted]
- **Gender:** [redacted]
- **Patient ID:** [redacted]

**Specimen Details**
- **Date collected:** 11/05/2020 1200
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

**Ordered Items**
- **SARS-CoV-2, NAA**

**Tests**
<table>
<thead>
<tr>
<th>SARS-CoV-2, NAA</th>
<th>Result</th>
<th>Flag</th>
<th>Units</th>
<th>Reference Interval</th>
<th>Lab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

---

01 SEQUO Integrated Genetics Sequenom

Dir: Phillip Cacheris, MDPhD

3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
Patient Details
DOB: [redacted]
Age(y/m/d): [redacted]
Gender: [redacted]
Patient ID: [redacted]

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Physician Details
Ordering: [redacted]
Referring: [redacted]
ID: [redacted]
NPI: [redacted]

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

Dir: Phillip Cacheris, MDPhD
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
Patient Details
DOB: [Redacted]
Age(y/m/d): [Redacted]
Gender: [Redacted]
Patient ID: [Redacted]

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Physician Details
Ordering:
Referring:
ID:
NPI:

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQC0 Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient’s recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
SARS-CoV-2, NAA

Not Detected

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient’s recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
SARS-CoV-2, NAA

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
### Patient Details
- **DOB:**
- **Age (y/m/d):**
- **Gender:**
- **Patient ID:**

### Specimen Details
- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

### Ordered Items
- **SARS-CoV-2, NAA**

### Tests
<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

---

**01 SEQCO Integrated Genetics Sequenom**
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact **Branch: 800-888-1113 Lab: 877-921-7266**
**Patient Details**
- **DOB:** [redacted]
- **Age (y/m/d):** [redacted]
- **Gender:** [redacted]
- **Patient ID:** [redacted]

**Specimen Details**
- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

**Physician Details**
- **Ordering:** [redacted]
- **Referring:** [redacted]
- **ID:** [redacted]
- **NPI:** [redacted]

**General Comments & Additional Information**
- **Total Volume:** Not Provided
- **Fasting:** No

**Ordered Items**
- **SARS-CoV-2, NAA**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
### Ordered Items

**SARS-CoV-2, NAA**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

---

**01 SEQCO Integrated Genetics Sequenom**

3595 John Hopkins Court, San Diego, CA 92121-1121

**Dir:** Phillip Cacheris, MDPhD

For inquiries, the physician may contact **Branch: 800-868-1113 Lab: 877-821-7266**
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

---

**SEQCO Integrated Genetics Sequenom**

3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact **Branch: 800-888-1113 Lab: 877-821-7266**
Patient Details
DOB: 11/05/2020
Age(y/m/d): 20
Gender: Male
Patient ID:

Ordered Items
SARS-CoV-2, NAA

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Physician Details
Ordering: LIBERSTEI
Referring:
ID:
NPI:

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

© 1995-2020 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00
# Patient Report

**Specimen ID:**

**Control ID:**

**Acct #:** 04122570  
**Phone:** (559) 852-2927  
**Rte:** 00

Kings Co Adult Jail  
1570 Kings Co Drive  
Hanford CA 93230

**Patient Details**

- **DOB:**  
- **Age (y/m/d):**  
- **Gender:**  
- **Patient ID:**

**Specimen Details**

- **Date collected:** 11/05/2020 1200 Local  
- **Date received:** 11/06/2020  
- **Date entered:** 11/06/2020  
- **Date reported:** 11/07/2020 0709 ET

**Physician Details**

- **Ordering:**  
- **Referring:**

**General Comments & Additional Information**

- **Total Volume:** Not Provided  
- **Fasting:** No

**Ordered Items**

- **SARS-CoV-2, NAA**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

**01 SEQCO Integrated Genetics Sequenom**

3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

---

**Date Issued:** 11/09/20 1114 ET  
**FINAL REPORT**

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 858-668-3700  
© 1995-2020 Laboratory Corporation of America® Holdings  
All Rights Reserved - Enterprise Report Version: 1.00
Patient Report

Specimen ID: [Redacted]
Control ID: [Redacted]

Acct #: 04122570  Phone: (559) 852-2927  Rte: 00

Kings Co Adult Jail
1570 Kings Co Drive
Hanford CA 93230

Patient Details
DOB: [Redacted]
Age(y/m/d): [Redacted]
Gender: [Redacted]
Patient ID: [Redacted]

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Physician Details
Ordering: [Redacted]
Referring: [Redacted]
ID: [Redacted]
NPI: [Redacted]

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01  SEQCO  Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient’s recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient’s recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Details**
- **DOB:** [Redacted]
- **Age:** [Redacted]
- **Gender:** [Redacted]

**Specimen Details**
- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

**Physician Details**
- **Ordering:** [Redacted]
- **Referring:** [Redacted]

**General Comments & Additional Information**
- **Total Volume:** Not Provided
- **Fasting:** No

**Ordered Items**
- SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

Date Issued: 11/09/20 1115 ET

Dir: Phillip Cacheris, MDPhD
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Report**

**Specimen ID:** [Redacted]

**Control ID:** [Redacted]

**Acct #:** 04122570  
**Phone:** (559) 852-2927  
**Rte:** 00

**Kings Co Adult Jail**  
1570 Kings Co Drive  
Hanford CA 93230

---

**Patient Details**

**DOB:** [Redacted]  
**Age (y/m/d):** [Redacted]  
**Gender:** [Redacted]  
**Patient ID:** [Redacted]

**Specimen Details**

**Date collected:** 11/05/2020 1200 Local  
**Date received:** 11/06/2020  
**Date entered:** 11/06/2020  
**Date reported:** 11/07/2020 0709 ET

**Physician Details**

**Ordering:**  
**Referring:**  
**ID:**  
**NPI:**

---

**General Comments & Additional Information**

**Total Volume:** Not Provided  
**Fasting:** No

---

**Ordered Items**

SARS-CoV-2, NAA

---

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

---

**01 SEQCO Integrated Genetics Sequenom**  
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

---

Date Issued: 11/09/20 1115 ET  
**FINAL REPORT**

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 858-668-3700

© 1995-2020 Laboratory Corporation of America® Holdings  
All Rights Reserved - Enterprise Report Version: 1.00
Patient Report

Specimen ID: [redacted] Control ID: [redacted]

Acct #: 04122570 Phone: (559) 852-2927 Rte: 00

Kings Co Adult Jail
1570 Kings Co Drive
Hanford CA 93230

Patient Details
DOB: [redacted] Age(y/m/d): [redacted] Gender: [redacted] Patient ID: [redacted]

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Physician Details
Ordering: LIBERSTEI Referring: ID: [redacted] NPI: [redacted]

General Comments & Additional Information
Total Volume: Not Provided Fasting: No

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

© 1995-2020 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
Patient Details
DOB: [redacted]
Age(y/m/d): [redacted]
Gender: [redacted]
Patient ID: [redacted]

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Physician Details
Ordering: [redacted]
Referring: [redacted]
ID: [redacted]
NPI: [redacted]

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121
For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

Dir: Phillip Cacheris, MDPhD

© 1995-2020 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00
**Patient Details**

- **DOB:** [Masked]
- **Age:** [Masked]
- **Gender:** [Masked]
- **Patient ID:** [Masked]

**Specimen Details**

- **Date collected:** 11/05/2020
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020

**Physician Details**

- **Ordering:** [Masked]
- **Referring:** [Masked]
- **ID:** [Masked]
- **NPI:** [Masked]

**Ordered Items**

- **SARS-CoV-2, NAA**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

---

**SEQCO Integrated Genetics Sequenom**

3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

---

Date Issued: 11/09/20 1115 ET

FINAL REPORT

Page 1 of 1

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 858-668-3700.

© 1995-2020 Laboratory Corporation of America Holdings
All Rights Reserved - Enterprise Report Version: 1.00
Patient Report

Specimen ID: [redacted]
Control ID: [redacted]

Kings Co Adult Jail
1570 Kings Co Drive
Hanford CA 93230

Patient Details
DOB: [redacted]
Age(y/m/d): [redacted]
Gender: [redacted]
Patient ID: [redacted]

Ordered Items
SARS-CoV-2, NAA

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Physician Details
Ordering: S GUSTAVESO
Referring: ID: LIBERSTEIN
NPI: 1598777559

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
Patient Details
DOB: [redacted] 
Age (y/m/d): [redacted]
Gender: [redacted]
Patient ID: [redacted]

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0813 ET

Physician Details
Ordering: 
Referring: 
ID: LIBERSTEIN
NPI: 

General Comments & Additional Information
Total Volume: Not Provided
Fasting: No

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360b-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

Dir: Phillip Cacheris, MDPhD
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient’s recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Details**

- **DOB:**
- **Age(y/m/d):**
- **Gender:**
- **Patient ID:**

**Specimen Details**

- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

**Physician Details**

- **Ordering:**
- **Referring:**
- **ID:**
- **NPI:**

**General Comments & Additional Information**

- **Total Volume:** Not Provided
- **Fasting:** No

**Ordered Items**

- SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**General Comments & Additional Information**

Total Volume: Not Provided

**Ordered Items**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

© 1995-2020 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Details**

DOB: [Redacted]  
Age [Redacted]:  
Gender: [Redacted]  
Patient ID: [Redacted]

**Specimen Details**

Date collected: 11/05/2020 1200 Local  
Date received: 11/06/2020  
Date entered: 11/06/2020  
Date reported: 11/07/2020 0709 ET

**Physician Details**

Ordering: S GUSTAVESO  
Referring: ID: LIBERSTEIN  
NPI: 1598777559

**Ordered Items**

SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01  SEQCO Integrated Genetics Sequenom  
Dir: Phillip Cacheris, MDPhD  
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 677-621-7266
**Patient Details**

- **DOB:**
- **Age (y/m/d):**
- **Gender:**
- **Patient ID:**

**Specimen Details**

- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

**Physician Details**

- **Ordering:** LIBERSTEI
- **Referring:**
- **ID:**
- **NPI:**

### Ordered Items

**SARS-CoV-2, NAA**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

---

**01 SEQCO Integrated Genetics Sequenom**

3595 John Hopkins Court, San Diego, CA 92121-1121

Dir: Phillip Cacheris, MDPhD

For inquiries, the physician may contact Branch: 800-868-1113 Lab: 877-821-7266

---

© 1995-2020 Laboratory Corporation of America® Holdings

All Rights Reserved - Enterprise Report Version: 1.00
**Patient Details**
- **DOB:** [redacted]
- **Age:** [redacted]
- **Gender:** [redacted]
- **Patient ID:** [redacted]

**Specimen Details**
- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

**Physician Details**
- **Ordering:** [redacted]
- **Referring:** [redacted]
- **ID:** [redacted]
- **NPI:** [redacted]

**General Comments & Additional Information**
- **Total Volume:** Not Provided
- **Fasting:** No

**Ordered Items**
- SARS-CoV-2, NAA

**Tests**

<table>
<thead>
<tr>
<th>Tests</th>
<th>Result</th>
<th>Flag</th>
<th>Units</th>
<th>Reference Interval</th>
<th>Lab</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQC0 Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

**Date Issued:** 11/09/20 1115 ET

**FINAL REPORT**

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 858-668-3700

© 1995-2020 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**Patient Details**

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOB</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Patient ID</td>
<td></td>
</tr>
</tbody>
</table>

**Specimen Details**

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date collected</td>
<td>11/05/2020 1200 Local</td>
</tr>
<tr>
<td>Date received</td>
<td>11/06/2020</td>
</tr>
<tr>
<td>Date entered</td>
<td>11/06/2020</td>
</tr>
<tr>
<td>Date reported</td>
<td>11/07/2020 0709 ET</td>
</tr>
</tbody>
</table>

**Physician Details**

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordering</td>
<td></td>
</tr>
<tr>
<td>Referring</td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td></td>
</tr>
<tr>
<td>NPI</td>
<td></td>
</tr>
</tbody>
</table>

**Ordered Items**

<table>
<thead>
<tr>
<th>Tests</th>
<th>Result</th>
<th>Flag</th>
<th>Units</th>
<th>Reference Interval</th>
<th>Lab</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

© 1995-2020 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00
Patient Details
DOB: [redacted]
Age(y/m/d): [redacted]
Gender: [redacted]
Patient ID: [redacted]

Specimen Details
Date collected: 11/05/2020 1200 Local
Date received: 11/06/2020
Date entered: 11/06/2020
Date reported: 11/07/2020 0709 ET

Physician Details
Ordering: [redacted]
Referring: [redacted]
ID: [redacted]
NPI: [redacted]

General Comments & Additional Information
Total Volume: Not Provided
Fasting: No

Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01  SEQCO  Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

Dir: Phillip Cacheris, MDPhD
**Patient Details**

- **DOB:** [redacted]
- **Age:** [redacted]
- **Gender:** [redacted]
- **Patient ID:** [redacted]

**Specimen Details**

- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

**Ordered Items**

- **SARS-CoV-2, NAA**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

---

**Physician Details**

- **Ordering:** [redacted]
- **Referring:** [redacted]
- **ID:** [redacted]
- **NPI:** [redacted]

**SEQCO Integrated Genetics Sequenom**

3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266

**Dir:** Phillip Cacheris, MDPhD

© 1995-2020 Laboratory Corporation of America® Holdings

All Rights Reserved – Enterprise Report Version: 1.00
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 SEQCO Integrated Genetics Sequenom

Dir: Phillip Cacheris, MDPhD

3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient’s recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td>01 SEQCO Integrated Genetics Sequenom</td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

Dir: Phillip Cacheris, MDPhD
01 SEQCO Integrated Genetics Sequenom
3595 John Hopkins Court, San Diego, CA 92121-1121

For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266
### Ordered Items

- **SARS-CoV-2, NAA**

### Specimen Details

- **Date collected:** 11/05/2020 1200 Local
- **Date received:** 11/06/2020
- **Date entered:** 11/06/2020
- **Date reported:** 11/07/2020 0709 ET

### Physician Details

- **Ordering:** LIBERSTEIN
- **Referring:** ID: LIBERSTEIN
  - **NPI:** TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
### General Comments & Additional Information
A courtesy copy of this report has been sent to 5595828546.

### Ordered Items
SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td>01</td>
<td>SEQCO Integrated Genetics Sequenom 01 3595 John Ho kins Court San Die o, CA 92121-1121 Dir. Phillip Cacheris, MDPhD For inquiries, the physician may contact Branch: 800-888-1113 Lab: 877-821-7266</td>
</tr>
</tbody>
</table>
This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.
**SARS-CoV-2, NAA**

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

---

**Final Report**

Date Issued: 01/05/21 2021 ET

For inquiries, contact Branch: 800-888-1113 Lab: 877-821-7266

---

© 1995-2021 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00